Hints and tips:
Related Topics
...Net income was $1.4bn, up from $373m in the same quarter the year before, when there was a large charge from the company’s collaboration with Nektar Therapeutics in immuno-oncology....
...Bristol and its partner Nektar Therapeutics, a San Francisco biotech, presented data from an earlier study on Saturday that showed the two drugs could shrink tumours in some patients....
...So far this month, the S&P 500 is up 6.5 per cent, with biotechs Nektar Therapeutics, Celgene (which are both no strangers to big share price moves) and oil company Hess the only three companies to have...
...The pharmaceuticals group will hand over $1.85bn in an upfront payment to Nektar Therapeutics, a San Francisco-based biotech group, in exchange for 35 per cent of global profits from its cancer medicine,...
...In one quirk, a move by S&P Dow Jones Indices to promote biotech company Nektar Therapeutics from the S&P 600 to the S&P 500 in mid-March has also had an effect on the indices’ relative performance....
...The advance in the shares of both companies helped push the S&P 500 pharmaceuticals sub-sector up 2.4 per cent though it was Nektar Therapeutics that notched the biggest gain on the sector for the day rising...
...The most promising experimental drug is from Nektar Therapeutics, a San Francisco biotech company that recently signed a record-breaking $1.85bn partnership deal with Bristol-Myers....
...Nektar Therapeutics, based in San Francisco, says the drug has a novel chemical structure which means it crosses the blood-brain barrier more slowly than traditional opioids such as Purdue Pharma’s OxyContin...
...Nektar Therapeutics also rose 13.1 per cent to $9.57 after the company entered into a licensing deal with AstraZeneca to develop two of its drugs....
...Instead, Pfizer was forced to write off $2.8bn and sell the rights back to Nektar Therapeutics, the original developer, after poor sales that were blamed on scepticism, limited evidence of benefit and an...
...Founded in 2003 with proceeds from the University of Bradford’s record £200m sale of a spin-off company, Bradford Particle Design, to the California pharmaceuticals company Inhale, now known as Nektar Therapeutic...
...Exubera, which is being co-developed by French drugmaker Sanofi-Aventis and Nektar Therapeutics of the US, has had to overcome significant questions, particularly on safety....
International Edition